Patient characteristics
| Characteristic . | N . | % . |
|---|---|---|
| Total enrolled and treated | 40 | |
| Median age (range), y | 59 (18-70) | |
| Female sex | 14 | 35.0 |
| Unrelated donor | 31 | 77.5 |
| PBMCs | 32 | 80.0 |
| Hematologic malignancy | 39 | 97.7 |
| Disease status at time of HCT | ||
| Remission | 26 | 65 |
| Persistent/progressive | 9 | 22.5 |
| Unclassified | 5 | 12.5 |
| HLA mismatch* | 7 | 17.5 |
| Conditioning | ||
| Myeloablative intensity | 23 | 57.5 |
| Radiation containing | 7 | 17.5 |
| Antithymocyte globulin containing | 1 | 2.5 |
| Median Karnofsky performance status (range), % | 60 (20-100) | |
| Target organ and severity grade | ||
| Skin | ||
| 1 | 3 | 7.5 |
| 2 | 9 | 22.5 |
| 4 | 7 | 17.5 |
| Liver (± skin ± gut) | ||
| 3 | 5 | 12.5 |
| 4 | 2 | 5 |
| Gut (± skin) | ||
| 3 | 9 | 22.5 |
| 4 | 5 | 12.5 |
| SR-aGVHD definition | ||
| No response to steroids | 21 | 52.5 |
| Progression with steroids | 15 | 37.5 |
| Protracted (unable to taper steroids) | 4 | 10 |
| Characteristic . | N . | % . |
|---|---|---|
| Total enrolled and treated | 40 | |
| Median age (range), y | 59 (18-70) | |
| Female sex | 14 | 35.0 |
| Unrelated donor | 31 | 77.5 |
| PBMCs | 32 | 80.0 |
| Hematologic malignancy | 39 | 97.7 |
| Disease status at time of HCT | ||
| Remission | 26 | 65 |
| Persistent/progressive | 9 | 22.5 |
| Unclassified | 5 | 12.5 |
| HLA mismatch* | 7 | 17.5 |
| Conditioning | ||
| Myeloablative intensity | 23 | 57.5 |
| Radiation containing | 7 | 17.5 |
| Antithymocyte globulin containing | 1 | 2.5 |
| Median Karnofsky performance status (range), % | 60 (20-100) | |
| Target organ and severity grade | ||
| Skin | ||
| 1 | 3 | 7.5 |
| 2 | 9 | 22.5 |
| 4 | 7 | 17.5 |
| Liver (± skin ± gut) | ||
| 3 | 5 | 12.5 |
| 4 | 2 | 5 |
| Gut (± skin) | ||
| 3 | 9 | 22.5 |
| 4 | 5 | 12.5 |
| SR-aGVHD definition | ||
| No response to steroids | 21 | 52.5 |
| Progression with steroids | 15 | 37.5 |
| Protracted (unable to taper steroids) | 4 | 10 |
<8/8 match at HLA A, B, and C and DRB1 loci.